These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 25002534)
1. TRP14 inhibits osteoclast differentiation via its catalytic activity. Hong S; Huh JE; Lee SY; Shim JK; Rhee SG; Jeong W Mol Cell Biol; 2014 Sep; 34(18):3515-24. PubMed ID: 25002534 [TBL] [Abstract][Full Text] [Related]
2. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. Hyeon S; Lee H; Yang Y; Jeong W Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472 [TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
4. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production. Lee SY; Lee KS; Yi SH; Kook SH; Lee JC PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641 [TBL] [Abstract][Full Text] [Related]
5. Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway. Wang N; Hao Y; Fu L Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235607 [TBL] [Abstract][Full Text] [Related]
6. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
7. Alternative NF-κB Regulates RANKL-Induced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent Mechanisms. Zeng R; Faccio R; Novack DV J Bone Miner Res; 2015 Dec; 30(12):2287-99. PubMed ID: 26094846 [TBL] [Abstract][Full Text] [Related]
8. Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells. Li DZ; Zhang QX; Dong XX; Li HD; Ma X J Bone Miner Metab; 2014 Sep; 32(5):494-504. PubMed ID: 24196871 [TBL] [Abstract][Full Text] [Related]
9. Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation. Kong X; Wu W; Yang Y; Wan H; Li X; Zhong M; Zhao H; Su X; Jia S; Ju D; Lin N J Transl Med; 2015 Mar; 13():91. PubMed ID: 25889035 [TBL] [Abstract][Full Text] [Related]
10. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling. Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531 [TBL] [Abstract][Full Text] [Related]
11. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice. Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355 [TBL] [Abstract][Full Text] [Related]
12. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways. Chen G; Xu Q; Dai M; Liu X Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598 [TBL] [Abstract][Full Text] [Related]
13. Protective Effects of Fermented Oyster Extract against RANKL-Induced Osteoclastogenesis through Scavenging ROS Generation in RAW 264.7 Cells. Jeong JW; Choi SH; Han MH; Kim GY; Park C; Hong SH; Lee BJ; Park EK; Kim SO; Leem SH; Jeon YJ; Choi YH Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901917 [TBL] [Abstract][Full Text] [Related]
14. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT. Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828 [TBL] [Abstract][Full Text] [Related]
15. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways. Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866 [TBL] [Abstract][Full Text] [Related]
16. Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells. Kharkwal G; Chandra V; Fatima I; Dwivedi A J Mol Endocrinol; 2012 Jun; 48(3):261-70. PubMed ID: 22493142 [TBL] [Abstract][Full Text] [Related]
17. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
18. Fucoidan, a sulfated polysaccharide, inhibits osteoclast differentiation and function by modulating RANKL signaling. Kim YW; Baek SH; Lee SH; Kim TH; Kim SY Int J Mol Sci; 2014 Oct; 15(10):18840-55. PubMed ID: 25334060 [TBL] [Abstract][Full Text] [Related]
19. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss. Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]